HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice by Esser, Alison K et al.




HTLV-1 viral oncogene HBZ induces osteolytic
bone disease in transgenic mice
Alison K. Esser
Washington University School of Medicine in St. Louis
Daniel A. Rauch
Washington University School of Medicine in St. Louis
Jingyu Xiang
Washington University School of Medicine in St. Louis
John C. Harding
Washington University School of Medicine in St. Louis
Michael H. Ross
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Esser, Alison K.; Rauch, Daniel A.; Xiang, Jingyu; Harding, John C.; Ross, Michael H.; Su, Xinming; Wu, Kevin; Xu, Yalin; Vij, Kiran;




Alison K. Esser, Daniel A. Rauch, Jingyu Xiang, John C. Harding, Michael H. Ross, Xinming Su, Kevin Wu,
Yalin Xu, Kiran Vij, Lee Ratner, Katherine N. Weilbaecher, and et al
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/6265
Oncotarget69250www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 41), pp: 69250-69263
HTLV-1 viral oncogene HBZ induces osteolytic bone disease in 
transgenic mice
Alison K. Esser1,*, Daniel A. Rauch1,*, Jingyu Xiang1, John C. Harding1, Nicole 
A. Kohart2, Michael H. Ross1, Xinming Su1, Kevin Wu1, Devra Huey2, Yalin Xu1, 
Kiran Vij1, Patrick L. Green2, Thomas J. Rosol2, Stefan Niewiesk2, Lee Ratner1 and 
Katherine N. Weilbaecher1
1 Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA
2 Department of Veterinary Biosciences, School of Veterinary Medicine, The Ohio State University, Columbus, OH, USA
* Co-authors
Correspondence to: Katherine N. Weilbaecher, email: kweilbae@wustl.edu
Keywords: HTLV-1, ATL, leukemia, HBZ, bone
Received: June 10, 2017 Accepted: August 03, 2017 Published: August 27, 2017
Copyright: Esser et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Adult T-cell leukemia/lymphoma (ATL) is an aggressive T cell malignancy that 
occurs in HTLV-1 infected patients. Most ATL patients develop osteolytic lesions 
and hypercalcemia of malignancy, causing severe skeletal related complications 
and reduced overall survival. The HTLV-1 virus encodes 2 viral oncogenes, Tax and 
HBZ. Tax, a transcriptional activator, is critical to ATL development, and has been 
implicated in pathologic osteolysis. HBZ, HTLV-1 basic leucine zipper transcription 
factor, promotes tumor cell proliferation and disrupts Wnt pathway modulators; 
however, its role in ATL induced osteolytic bone loss is unknown. To determine if HBZ 
is sufficient for the development of bone loss, we established a transgenic Granzyme 
B HBZ (Gzmb-HBZ) mouse model. Lymphoproliferative disease including tumors, 
enlarged spleens and/or abnormal white cell counts developed in two-thirds of Gzmb-
HBZ mice at 18 months. HBZ positive cells were detected in tumors, spleen and bone 
marrow. Importantly, pathologic bone loss and hypercalcemia were present at 18 
months. Bone-acting factors were present in serum and RANKL, PTHrP and DKK1, key 
mediators of hypercalcemia and bone loss, were upregulated in Gzmb-HBZ T cells. 
These data demonstrate that Gzmb-HBZ mice model ATL bone disease and express 
factors that are current therapeutic targets for metastatic and bone resident tumors.
INTRODUCTION
Viral infections cause some of the most common 
malignancies worldwide including human papillomavirus 
(cervical cancer), hepatitis B and C viruses (liver cancer), 
and Epstein-Barr virus (lymphoma). The understanding 
of viral oncogene functions has uncovered important 
basic mechanisms of tumor biology that have been used 
to prevent and treat cancer. Human T cell Leukemia/
Lymphoma Virus 1 (HTLV-1) is the only human retrovirus 
known to directly cause cancer [1]. Adult T cell leukemia/
lymphoma (ATL) is an aggressive lymphoproliferative 
malignancy of T cells that develops in a subset of HTLV-1 
infected patients usually after decades of clinical latency. 
The acute form is refractory to aggressive chemotherapy 
treatments and has a mean survival time of less than one 
year, demonstrating the need to better understand this 
disease [2-4].
The HTLV-1 genome contains 2 viral oncogenes, 
Tax and HBZ. Tax has oncogenic properties in mouse 
models of ATL [5, 6]. Tax is a transcription factor that 
acts as a co-activator for CREB binding proteins [7]. 
Enhanced NFAT-1, AP-1 and NF-κB pathway activation 
by Tax regulates lymphocyte proliferation and apoptosis 
[8, 9]. In addition, Tax facilitates virus transmission and 
increases genomic instability [10, 11]. Tax is highly 
immunogenic and expression is repressed in human ATL 
cells [12, 13]. While the oncogenic properties of Tax have 
been extensively investigated, HBZ was only identified as 
a viral oncogene within the last 15 years. HBZ is a helix-
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basic loop zipper protein transcribed from the antisense 
strand of the HTLV-1 genome. HBZ acts as a transcription 
factor to negatively regulate Tax and is the only viral 
protein expressed in both early and late stages of human 
ATL [14, 15]. HBZ regulates cellular proliferation, reduces 
cellular aging and inhibits senescence of infected cells 
through enhanced expression of hTERT and JunD and 
inhibition of p65 and p53 [16-19]. HBZ can also impair 
expression of DICER and some miRNAs through removal 
of JunD from the DICER promoter [20]. Recent reports 
demonstrate that HBZ has oncogenic and inflammatory 
properties in animal models [21, 22]. 
In addition to leukemia/lymphoma, many HTLV-
1 associated ATL patients develop paraneoplastic 
hypercalcemia and osteolytic bone lesions, which 
commonly occur in metastatic solid tumors such as breast 
and prostate, but is much less common in hematologic 
malignancies [23, 24]. Inhibiting bone loss in patients 
with bone metastases and multiple myeloma, reduced 
bone fracture, bone pain and improved quality of life [25]. 
We have previously reported that Tax transgenic mice 
under the Granzyme B promoter model many aspects of 
human ATL and that osteoclast inhibitors could inhibit 
the hypercalcemia and osteolytic bone lesions in these 
mice [5, 26, 27]. However, Tax protein is infrequently 
detected in primary human ATL cells, even in patients with 
hypercalcemia and osteolytic bone lesions. We therefore 
determined if HBZ, which is constitutively expressed 
in most human ATL cells, affects osteoclasts and bone, 
independent of Tax. As we did for the Tax transgenic 
mice, we have generated mice expressing HBZ under 
the Granzyme B promoter (Gzmb-HBZ). ATL is a T cell 
malignancy and the Granzyme B promoter specifically 
targets HBZ expression to T cells and NK cells.
We found that Gzmb-HBZ mice developed 
spontaneous, palpable tumors, enlarged spleens and/
or abnormal white blood cell counts at 18 months. 
Tumors were primarily composed of hematopoietic 
cells and included HBZ expressing cells, which were 
also present in the spleen and bone marrow. Gzmb-HBZ 
lymphoproliferative disease was transplantable into both 
Gzmb-HBZ and NSG mice. Importantly, Gzmb-HBZ 
mice had significant bone loss and hypercalcemia of 
malignancy, analogous to the pathologic bone destruction 
and hypercalcemia present in ATL patients. Inflammatory 
cytokines and cytokines that have been shown to effect 
bone (IL-6, IL-3, MCP-1) were increased in serum from 
Gzmb-HBZ mice. Splenic T cells had increased expression 
of factors known to promote bone loss, including RANKL, 
PTHrP and DKK1. Importantly, these factors are the target 
of therapies for bone metastases and multiple myeloma 
[28].
RESULTS
Gzmb-HBZ mice develop spontaneous tumors
HTLV-1 Tax transgenic mice develop leukemia and 
osteolytic disease; however, Tax is frequently repressed 
in late-stage HTLV-1 associated ATL when pathologic 
bone disease develops. The HTLV-1 viral gene, HBZ, is 
expressed at both early and late stages of human ATL and 
has been shown to cause expression of factors that can act 
on bone in vitro [29]. To evaluate the effect of HBZ on 
tumor development and bone loss in vivo, we generated 
transgenic mice expressing HBZ under the Granzyme B 
promoter (Gzmb-HBZ) (Figure 1A). To validate targeted 
HBZ expression, mRNA from Gzmb-HBZ and WT 
mouse T cells was measured. T cells were enriched using 
magnetic bead isolation from whole spleen and activated 
by culture on CD3/CD28 coated plates for 24 hours ex 
vivo to increase Granzyme B and HBZ expression. Gzmb-
HBZ T cells expressed HBZ mRNA by qPCR analysis 
(Figure 1B). HBZ was not detected in T cells from WT 
mice. 
To determine the oncogenic potential of HBZ in 
this model, 4-, 12- and 18-month cohorts of WT and 
Gzmb-HBZ mice were evaluated for tumor development, 
spleen size, complete blood counts (CBCs) and white cell 
differentials. There was no difference in these parameters 
between WT and Gzmb-HBZ mice at 4- and 12-months 
of age (Supplementary Figure 1A-1C). However, at 18 
months, 40% of Gzmb-HBZ mice developed spontaneous 
tumors primarily localized to mesenteric and lymphoid 
tissues (Figure 1A, 1C). Spleen size was increased in 
Gzmb-HBZ tumor bearing mice (307 ± 52 mg, n = 7) 
compared to non-tumor bearing Gzmb-HBZ controls (142 
± 13 mg, n = 8) (Figure 1D). White blood cell (WBC) 
counts were assessed in Gzmb-HBZ and WT mice. The 
normal range was determined as the WT mean value 
+/- 2 standard deviations. 36% of Gzmb-HBZ mice had 
WBC counts outside of the normal range of 3.5 +/- 1.9 K/
µl (Gzmb-HBZ WBC values of 0.8, 6.9, 8.4, 18.9 K/µl). 
All WT mice were within the normal range (Figure 1E). 
These data indicate that 66% of Gzmb-HBZ mice develop 
disease with overt tumors or lymphocyte abnormalities by 
18 months. 
Gzmb-HBZ mice develop lymphoproliferative 
disease that is transplantable
Tumors from Gzmb-HBZ mice were evaluated 
by immunohistochemistry (IHC) and flow cytometry. 
By IHC, Gzmb-HBZ tumors were composed of CD45+ 
hematopoietic cells including B220+ cells (B cells/
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activated T cells) and CD3e+ cells (T cells) (Figure 2A). 
Flow cytometry analysis of tumors from Gzmb-HBZ mice 
(n = 4) was performed to evaluate T cell subpopulations. 
Similar to IHC, 98.5% cells were hematopoietic (CD45+). 
Of the CD45+ cells, 27.5% were T cells (CD3e+) and 66% 
were B cells (CD19+) (Figure 2B). Of the CD3e+ T cell 
population, 41% were CD8+ T cells and 53% were CD4+ 
T cells. 35% of CD4+ cells were CD25+ T regulatory 
cells. These data demonstrate that a significant percent of 
cells in Gzmb-HBZ tumors were hematopoietic. 
In this model, HBZ is flag-tagged and expressed 
in hematopoietic cells as a transgene regulated by the 
Granzyme B promoter. We therefore assessed HBZ 
expression in tumors and hematopoietic tissues including 
spleen and bone marrow by IHC. Expression of the flag 
epitope was detected in Gzmb-HBZ tumors using an anti-
flag antibody (Figure 2C). Flag-HBZ positive cells were 
present in Gzmb-HBZ spleen and bone marrow of tibiae 
at 18 months. Flag-HBZ positive cells were not detected 
in the spleens of 4-month old mice (Supplementary Figure 
1D). Two Gzmb-HBZ mice developed either a hepatic 
tumor or an epidermal tumor, both comprised of cells 
expressing cytokeratin (epithelial) but low levels of CD45. 
Flag-HBZ was not detected by IHC in these tumors. To 
confirm HBZ expression, HBZ RNA was detected by 
in situ hybridization. HBZ RNA was present in 12-25% 
of cells from Gzmb-HBZ derived tumors (Figure 2D 
and Supplementary Figure 1E). These data confirm that 
Gzmb-HBZ mice develop lymphoproliferative disease 
with localization of HBZ expressing cells to tumors and 
other hematopoietic tissues at 18 months.
A hallmark of malignant transformation is whether a 
transplanted tumor can proliferate in another host. Tumor 
cells from a primary Gzmb-HBZ mesenteric tumor (Figure 
2B) or PBS were injected intravenously (iv) into NSG (n 
= 6) mice, which lack functional T cells, B cells, and NK 
cells, to look at proliferative and metastatic potential. 
Tumor development was assessed 2 months post tumor 
cell implantation. While overt tumors were not visible at 
2 months, tumor cell implanted mice did develop enlarged 
spleens (110 ± 20 mg) compared to PBS injected controls 
(40 ± 2 mg) (Figure 3A). Flow cytometry analysis of 
splenocytes revealed a substantial difference in the percent 
of CD4+ and CD8+ T cells in HBZ tumor cell transplanted 
mice (1.6 ± 0.7, 6.3 ± 7.1, n = 3) versus PBS controls (0.36 
± 0.12, 0.12 ± 0.03, n = 3) (Figure 3B, 3C), indicating 
CD4 and CD8 T cells are transplantable. 
We next evaluated whether Gzmb-HBZ tumor 
Figure 1: Granzyme B HBZ mice develop lymphoproliferative disease. A. Granzyme B HBZ plasmid schematic and Gzmb-
HBZ mouse. Arrow denotes a mesenchymal lymph node tumor in a Gzmb-HBZ mouse. B. HBZ mRNA expression in 4 month old WT and 
Gzmb-HBZ mice by Real-Time RT-PCR. C. Tumor incidence in 18-month WT and Gzmb-HBZ mice. D. Spleen weight in Gzmb-HBZ 
tumor free (n = 8) and tumor-bearing mice (n = 7). E. Percent of WT (n = 7) and Gzmb-HBZ (n = 15) mice with normal white blood cell 
counts (WBC). Normal WBC range was determined as the WT median +/- 2 standard deviations. B.-D. Statistical analysis represents mean 
+/- SEM. Statistical significance determined by non-parametric student’s t-test B., D. or Fisher’s exact test C., E. as appropriate. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001.
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derived cells could be serially passaged in mice. Gzmb-
HBZ cells derived from the primary mesenteric tumor 
(Figure 2B) were implanted into the peritoneal cavity 
of a Gzmb-HBZ mouse. At 2 months post injection, a 
palpable tumor was detected at the injection site (Figure 
3D). The Gzmb-HBZ implanted mouse had increased 
Figure 2: Lymphoid derived Gzmb-HBZ tumors express HBZ. A. Gzmb-HBZ tumor immunohistochemistry (IHC) for 
hematopoietic (CD45), T cells (CD3e) and B/activated T cells (B220) in a thoracic lymph node-derived tumor. Scale bar = 50 µm. B. Flow 
cytometry analysis of T cell populations in a Gzmb-HBZ derived mesenteric lymph node tumor. C. Flag-HBZ expression in tumor, spleen 
and tibia of Gzmb-HBZ mice by IHC. Scale bar = 20 µm. D. HBZ RNA in Gzmb-HBZ tumor cells by in situ hybridization, representative 
images and quantification. Scale bar = 50 µm.
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spleen and thymus weights compared to the PBS injected 
control, supporting transplant of lymphoproliferative cells 
(Figure 3E, 3F). To distinguish implanted tumor cells 
from host cells, tumor cells from the secondary tumor 
were implanted into NSG mice (n = 5/group). Tumor 
cells or WT splenocytes were injected intravenously to 
determine metastatic potential. At 2 months post injection, 
overt metastases were not apparent. Splenocyte T cell 
populations were assessed by flow cytometry. CD3e+ T 
cells were detected in tumor cell implanted mice but were 
not detected in WT splenocyte implanted mice (Figure 
3G). Tumor-transplanted mice had measurable CD4+ T 
cells and substantial CD8+ T cells present (Figure 3H). 
Together, these data demonstrate that cells derived from 
tumors in Gzmb-HBZ mice were transplantable.
Decreased bone volume and hypercalcemia in 
Gzmb-HBZ mice
ATL is associated with bone loss and hypercalcemia 
of malignancy; therefore, bone loss was evaluated in 
the Gzmb-HBZ mice. Initial X-ray comparison of tibiae 
suggested Gzmb-HBZ had reduced bone compared to WT 
mice at 18 months (Figure 4A). At 4 and 12 months of 
age, 2 parameters of bone loss, bone volume/tissue volume 
(BV/TV) and trabecular thickness (Tb.Th.), were similar 
between WT and Gzmb-HBZ mice by microCT analysis 
(Figure 4B and Supplementary Figure 2A, 2B). By 18 
months, BV/TV was significantly reduced in Gzmb-HBZ 
mice (-66%) compared to WT mice (0.06 ± 0.01, 0.18 ± 
0.03). Tb.Th was also reduced in Gzmb-HBZ mice (-30%) 
Figure 3: T cells from Gzmb-HBZ mice are transplantable. A. Spleen weights from NSG mice implanted intravenously with PBS 
or mesenteric lymph node tumor cells (n = 5/group). B. Splenic CD4 and C. CD8 T cells from sham or tumor implanted mice. D. Image of a 
Gzmb-HBZ mouse 2-months post intraperitoneal tumor cell implantation with corresponding spleen weight E. and thymus weight F. *Red 
asterisk denotes a tumor. Percent of splenic CD3e T cells G. or CD4 and CD8 H. T cells from NSG mice serially implanted with tumor cells 
(D) or WT splenocytes (n = 5/group). All data reported as mean +/- SEM with statistical significance determined by Mann-Whitney U-test 
A. or unpaired t-test B. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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compared to WT mice (0.07 ± 0.002 mm, 0.1 ± 0.003 mm) 
(Figure 4C, 4D). Osteoclasts (OC) are bone-resorbing 
cells frequently increased in number and function in 
ATL patients and patients with bone metastases. To 
determine if the OC number or OC surface/bone surface 
(OC.S/BS) was changed in Gzmb-HBZ mice, tartrate-
resistant acid phosphatase (TRAP) stains of OC from 
histological sections of bone were evaluated. Osteoclast 
surface/bone surface (OC.S/BS) but not OC number 
(OC.N) was significantly increased in Gzmb-HBZ mice, 
suggesting enhanced bone resorption (Figure 4E, 4F and 
Supplementary Figure 2C). Some cancer cells modulate 
the bone microenvironment by altering the activity of bone 
forming osteoblasts. Procollagen Type I Intact N-terminal 
Propeptide (P1NP) is released during bone formation 
and can be used as a marker for osteoblast activity. WT 
and Gzmb-HBZ mice had similar levels of serum P1NP, 
indicating bone formation at 18 months is unchanged 
with HBZ expression (Figure 4G). Hypercalcemia 
due to resorption of bone is a serious complication for 
ATL patients. Serum calcium levels were significantly 
increased in Gzmb-HBZ mice (10.8 ± 0.53) compared to 
WT controls (8.62 ± 0.31) (Figure 4H). Thus, Gzmb-HBZ 
mice model the lymphoproliferative disease, bone loss and 
hypercalcemia present in HTLV-1 associated ATL. 
Figure 4: Gzmb-HBZ mice develop bone loss and hypercalcemia. A. Representative X-ray images of WT and Gzmb-HBZ 
tibiae. MicroCT analysis of bone volume/tissue volume (BV/TV) and trabecular thickness (Tb.Th) at 4 months of age (n = 5/group) B. and 
18 months of age C. in WT (n = 7) and Gzmb-HBZ (n = 13) mice. D. MicroCT representative images. Scale bar = 300 µm. TRAP+ cells 
(arrowheads) E. and quantification of osteoclast surface per bone surface F. in WT (n = 5) and Gzmb-HBZ (n = 3) tibiae. Scale bar = 50 µm. 
G. Enzyme-linked immunosorbent assay (ELISA) for osteoblast activity marker Procollagen Type I Intact N-terminal Propeptide (P1NP), 
measured in serum from Gzmb-HBZ (n = 4) and WT (n = 7) mice. H. Serum calcium levels in WT (n = 5) and Gzmb-HBZ (n = 4) mice at 18 
months. All data reported as mean +/- SEM. Statistical significance was determined by unpaired t-test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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Figure 5: Gzmb-HBZ mice have systemic inflammation and increased T-cell derived bone-acting factors. A. ELISA 
quantification of serum cytokines in 18-month WT (n = 3) and Gzmb-HBZ (n = 3) mice. Flow cytometry analysis of ex vivo expanded T cell 
populations B. and IFNγ expression C. from WT and Gzmb-HBZ splenocytes. Granzyme B D., HBZ E., PTHrP F., RANKL G. and DKK1 
H. mRNA expression in WT and Gzmb-HBZ ex vivo cultured, activated T cells. Data is representative of 2-3 biological replicates. All data 
reported as mean +/- SEM. Statistical significance determined by unpaired t-test. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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Gzmb-HBZ mice have increased inflammatory 
and bone-acting cytokines in serum
Chronic inflammation and cancer can cause bone 
loss through multiple mechanisms. Tumors can secrete 
factors that act directly on bone resorbing osteoclasts 
(OC) or can have indirect effects on OCs through other 
cell types in the bone microenvironment. Serum from 
18-month old, fasted Gzmb-HBZ (n = 3) and WT (n = 
3) mice was analyzed for changes in cytokines and 
chemokines using a quantitative glass-slide antibody array. 
Inflammatory cytokines IFNγ and IL-6 were significantly 
increased in serum from Gzmb-HBZ mice compared 
to WT mice (Figure 5A). Furthermore, multiple factors 
that have been shown to directly and indirectly affect 
bone were significantly increased in Gzmb-HBZ mice 
compared to WT mice, including IL-6, MCP-1, and IL-3. 
Several factors trended toward increased levels in serum 
of Gzmb-HBZ mice such as IL-17, RANTES and IL-1β 
but did not reach statistical significance. The concentration 
of IL-2 in serum was similar between Gzmb-HBZ and WT 
mice, demonstrating that cytokines upregulated in Gzmb-
HBZ transgenic mice were enriched in inflammatory and 
bone-acting factors. 
To determine whether T-cells from HBZ mice 
express inflammatory factors, splenocytes from WT and 
Gzmb-HBZ mice were isolated and activated in culture 
on CD3/CD28 coated tissue culture plates followed by 
expansion in IL-2 containing media. Similar to CD8 T 
cell expansion in Gzmb-HBZ tumor cell transplanted 
mice, CD8 T cells were substantially increased in Gzmb-
HBZ ex vivo T cell cultures (Figure 5B). Further, CD8 but 
not CD4 T cells had enhanced IFNγ by flow cytometry 
analysis (Figure 5C), demonstrating increased serum 
inflammatory factors in Gzmb-HBZ mice may in part be 
due to enhanced T cell expression.
Parathyroid hormone related protein (PTHrP) is 
an important mediator of hypercalcemia and osteolytic 
bone loss through upregulation of RANKL whereas; the 
Dickkopf-WNT signaling pathway inhibitor 1 (DKK1) 
inhibits osteoblast bone formation, thus altering the 
bone resorption/bone formation balance of the bone 
microenvironment towards osteolytic bone loss. To 
evaluate the effects of HBZ expression in T cells on 
expression of these bone modifying proteins, splenocytes 
from WT and Gzmb-HBZ mice were isolated and 
expanded in culture on CD3/CD28 coated tissue culture 
plates for 24hrs. Granzyme B and HBZ expression were 
increased in Gzmb-HBZ T cells compared to WT (Figure 
5D, 5E). We then measured PTHrP, RANKL and DKK1 
mRNA, which activate osteoclasts and inhibit osteoblast 
function to promote bone loss. PTHrP, RANKL and DKK1 
mRNA were significantly increased in T cells from Gzmb-
HBZ mice compared to WT controls (Figure 5F-5H). 
Thus, HBZ may enhance expression of bone-acting serum 
cytokines and other factors known to have osteolytic 
effects on bone and are targeted by current therapeutics.
DISCUSSION
HTLV-1 induced ATL is associated with significant 
skeletal complications including hypercalcemia and 
osteolytic bone lesions. The HTLV-1 viral oncogene, 
Tax, regulates the expression of osteoclast-acting 
factors and may be a primary driver of bone pathology 
in ATL. We show for the first time, that HBZ transgenic 
mice also develop pathologic bone loss in addition to 
lymphoproliferative disease, suggesting that HBZ may 
also play a causative role in the pathogenesis of ATL 
induced bone loss. HBZ is a particularly compelling 
candidate for pathologic bone loss in ATL because 
Tax expression is frequently repressed in ATL cells, 
particularly at later stages, while HBZ is ubiquitously 
expressed in ATL cells and in all ATL disease stages [14].
We evaluated 4, 12 and 18-month cohorts of 
Granzyme B HBZ (Gzmb-HBZ) mice for tumor formation 
and bone loss. Tumors and hematopoietic changes were 
not evident until the 18-month time point. Interestingly, 
there is also a long latency between HTLV-1 infection 
and the development of ATL. We found that two-thirds 
of Gzmb-HBZ mice developed lymphoproliferative 
disease including palpable tumors, enlarged spleen and/
or abnormal white blood cell counts. Overt tumors were 
present primarily in lymphoid and mesenteric tissues 
and were composed of significant numbers of CD45+ 
hematopoietic cells including CD3e+ T cells that 
encompass both CD4 and CD8 T cells.
We observed several key similarities between our 
Gzmb-HBZ mice and recently published CD4-HBZ 
transgenic mice [21]. The CD4-HBZ mice develop 
leukemia at older ages, around 16 months, with changes 
in hematopoietic profiles, splenic infiltration and systemic 
inflammation, as was observed in the Gzmb-HBZ mice. 
We also observed HBZ expression in CD4 T cells from 
Gzmb-HBZ mice. In contrast, enlarged lymph node tumors 
were characteristic of the Gzmb-HBZ mice, but were not 
reported in the CD4-HBZ mice. Further, CD4-HBZ mice 
developed dermatitis not present in the Gzmb-HBZ model. 
The different expression patterns between CD4 (CD4 T 
helper cells) and Granzyme B (mature cytotoxic T and 
NK cells) promoters may explain some of the phenotypic 
differences seen in these models. 
Interestingly, independent expression of HTLV-
1 oncogenes Tax and HBZ by the same promoter, 
Granzyme B, resulted in very different tumor phenotypes 
in transgenic mice. Although both developed tumors 
in lymphatic tissues, Gzmb-HBZ mice did not develop 
the peripheral subcutaneous tumors characteristic of 
Granzyme B Tax mice [5]. This may in part be attributed 
to the previously reported weaker oncogenic potential 
of HBZ compared to Tax. Indeed, HBZ mice develop 
lymphoproliferative disease after an 18-month latency as 
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compared to the 6-9 month latency to malignancy in the 
Granzyme B Tax mice, further supporting that Tax is a 
more potent oncogene. 
Characterization of malignant cells within 
tumors was more challenging than anticipated. NSG 
mice transplanted with cells from a primary Gzmb-
HBZ tumor had detectable CD4 and CD8 T cells in the 
spleen. NSG mice implanted with serially passaged 
tumor cells, had measurable CD4 T cells present and 
substantial expansion of CD8+ T cells, suggesting 
lymphoproliferative disease was transplantable, a hallmark 
of malignant transformation. Importantly, Granzyme B 
is highly expressed in CD8 T cells and is expressed in 
some cytotoxic CD4 subsets. Recent studies have found 
that in HTLV-1 infected patients, infected CD8+ T cell 
undergo greater oligoclonal proliferation than infected 
CD4+ cells, however; CD8+ ATL is rare suggesting that 
clonal T-cell proliferation does not predispose patients 
to malignant disease [30]. In the CD4-HBZ transgenic 
mouse model, an ATL stem cell candidate (c-kit+/CD4-/
CD8-) was identified and the c-kit-SCF signaling pathway 
was implicated in leukemia development. It would be 
interesting to determine if this population is present in the 
serially transplanted Gzmb-HBZ lymphoproliferative cell 
population [31].
Cells within Gzmb-HBZ tumors expressed HBZ 
protein and RNA. HBZ positive cells comprised a small 
number of total cells, making characterization of the 
malignant cells within tumors more difficult. It is possible 
that HBZ expression was lost in tumors, perhaps through 
promoter methylation [32]. Experiments using inducible 
systems could address the necessity of persistent HBZ 
expression and tumor formation. Another possibility 
is that low HBZ expression in the tumor could indicate 
that HBZ is indirectly effecting tumor formation through 
inflammation or other signaling pathways. Inflammation 
has been reported to increase tumor formation and loss 
of IL-15 promoted tumor development in the Granzyme 
B Tax model [33]. Importantly, the CD4-HBZ transgenic 
model also reported systemic inflammation that 
contributed to leukemia onset [21, 34]. We similarly found 
that the Gzmb-HBZ transgenic mice had inflammatory 
cytokines in the serum and in ex vivo T cell cultures. Thus, 
it is possible that indirect HBZ-mediated effects caused 
tumors in Gzmb-HBZ mice. Future studies will interrogate 
the role of HBZ and HBZ-associated factors in malignant 
transformation and tumor formation in transplantation 
studies. In addition, it has recently been reported that 
HBZ protein and RNA have distinct functions in T-cell 
proliferation and survival. HBZ protein has been 
shown to regulate transcription of immune-associated 
genes while RNA was associated with genes related to 
cell proliferation. It will be important to delineate the 
differential effects of RNA and protein on oncogenesis and 
bone loss in HTLV-1 associated ATL [15, 35].
In Gzmb-HBZ transgenic mice, development 
of bone loss and hypercalcemia coincided with 
lymphoproliferative disease, demonstrating HBZ-mediated 
bone loss in vivo for the first time. Bone is continuously 
remodeled and the process of bone resorption (osteoclasts) 
and bone formation (osteoblasts) is tightly coupled. Some 
diseases including cancer disrupt this coupling causing a 
net increase (prostate cancer) or decrease (breast cancer) 
of bone. Although osteoclast number was unchanged in 
Gzmb-HBZ and WT mice, osteoclast size was increased 
in Gzmb-HBZ mice. OC size is measured by length on the 
bone surface and a larger size can represent an increase in 
resorptive surface and accelerated bone loss. Osteoblast 
activity measured by serum collagen marker P1NP, was 
similar between Gzmb-HBZ and WT. It has been reported 
that by 18 months, there is little bone formation and this 
may explain why there was no difference in the osteoblast 
activity marker P1NP between WT and Gzmb-HBZ mice. 
Of note, Gzmb-HBZ tibiae did not have osteolytic lesions 
characteristic of a localized tumor effect but instead 
had an overall thinning of the trabeculae representative 
of systemic bone loss seen in some types of cancer, 
including breast cancer. We have previously shown that 
Tax transgenic mice (under the Granzyme B promoter) 
develop bone loss and hypercalcemia by 9 months of 
age. We now demonstrate that HBZ expression can have 
significant effects on bone loss, independent of Tax or 
other viral pathogenesis factors. 
Since significant lymphoproliferative disease was 
not present in the bone marrow of Gzmb-HBZ mice and 
cells that express HBZ were detectable in bone marrow 
in only limited numbers, we assessed expression of bone-
acting and pro-inflammatory factors in serum. Cytokines 
have important effects on bone resorptive osteoclasts and 
can induce systemic bone loss [25]. We found that factors 
known to promote bone loss in solid and hematologic 
cancers (IL-6, MCP-1 and IL-3) were significantly 
elevated serum from Gzmb-HBZ mice compared to WT 
mice, indicating HBZ-mediated changes in cytokine 
secretion may directly or indirectly accelerate bone loss 
in this model. In addition, chronic inflammation causes 
osteolytic bone loss in diseases such as rheumatoid 
arthritis. Gzmb-HBZ mice had elevated levels of serum 
inflammatory cytokines and inflammation could contribute 
to bone loss in this model. 
Several factors including, IL-1, MIP1α, RANKL 
and PTHrP, have been implicated in ATL mediated 
hypercalcemia and bone loss. Parathyroid hormone-related 
protein (PTHrP) induces hypercalcemia and systemic 
bone loss, in part, through upregulation of RANKL, a 
critical factor in osteoclast formation, and enhanced bone 
resorption. PTHrP expression is increased in HTLV-
1 infected cell lines, patient serum and in primary ATL 
cells, however little is known about the regulation of 
PTHrP expression by the HTLV-1 virus [23]. We found 
that in addition to Granzyme B and HBZ, PTHrP was 
significantly increased in T cells isolated from Gzmb-
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HBZ mice, providing the first in vivo evidence that 
HBZ could mediate hypercalcemia through enhanced 
PTHrP expression. Receptor activator of nuclear factor 
kappa-B ligand (RANKL) expression by some tumor 
types increases osteoclast formation and promotes 
bone resorption. Overexpression of the RANKL gene 
in ATL patients correlates with hypercalcemia [36]. In 
our transgenic mouse model, RANKL expression was 
significantly increased compared to WT mice, supporting 
a potential role for RANKL in HTVL-1 mediated bone 
loss. In addition, expression of the WNT pathway inhibitor 
Dickkopf-1 (DKK1) was increased by HBZ expression 
in vitro [29]. DKK1 inhibits bone-forming osteoblasts 
to promote bone loss in metastatic and hematopoietic 
malignancies [37]. We found that DKK1 expression was 
also increased in Gzmb-HBZ T cells compared to WT 
controls in vivo, suggesting HBZ may directly or indirectly 
effect DKK1 expression. Thus, in the Gzmb-HBZ mouse 
model, expression of PTHrP, RANKL and DKK1, known 
inducers of hypercalcemia and bone loss and therapeutic 
targets for osteoporosis and cancer, were increased in T 
cells. 
In this work, we have shown that Gzmb-HBZ mice 
developed lymphoproliferative disease and model the 
bone loss and hypercalcemia present in ATL patients. 
We further identified elevated bone-acting factors in both 
serum and T cells from Gzmb-HBZ mice. Importantly, 
these factors have established roles in pathologic bone 
loss in osteoporosis, metastatic cancer and chronic 
inflammatory diseases. We thus demonstrated for the first 
time in an animal model, that the HTLV-1 oncogene HBZ 
might have an important role in ATL-mediated bone loss 
independent of Tax and suggest that HBZ-mediated bone 
loss may respond to current therapies for bone resident 
and metastatic tumors. Additional studies are needed to 
evaluate the effects of HBZ on bone loss in the context of 
the entire HTLV-1 genome.
MATERIALS AND METHODS
Animal studies
An independent transgenic Gzmb-HBZ mouse 
colony was derived and bred in the Weilbaecher lab from 
TAX-Luciferase-HBZ transgenic mice (C57Bl/6J; FVB), 
a generous gift from Dr. Lee Ratner. In the TAX-Luc-HBZ 
model (unpublished), the Granzyme B promoter regulates 
TAX and HBZ expression. The 5’LTR fragment of pHTE-
1 regulates firefly luciferase (pGL-3; Promega). Individual 
Granzyme B TAX [5] and Granzyme B TAX-Luc [38] 
strains have been previously described. For evaluation, 4, 
12 and 18-month cohorts of WT (n = 8), and Gzmb-HBZ 
mice (n = 8) were generated. A second cohort of 18-month 
Gzmb-HBZ mice was generated to facilitate evaluation 
of tumor heterogeneity (n = 7). Cohorts consisted of 
equal numbers of male and female mice. Animals were 
housed under pathogen-free conditions according to the 
guidelines of the Division of Comparative Medicine, 
Washington University (St. Louis, MO). Animal studies 
were performed under protocols approved and monitored 
by the Washington University Institutional Animal Care 
and Use Committee.
Construction of the HBZ transgene
The Granzyme B promoter flanked by EcoRV 
sites (using DRGZBL and DRGZBR primers shown) 
was inserted into the SnaBI linearized pHBZ1 
plasmid [39] . The purified 2.7kb transgene (produced 
using DRGZBL and DRGZBHBZR primers) was 





RNA was extracted from either cells or frozen tissue 
homogenized by mortar and pestle using the RNeasy Mini 
kit (Qiagen, Venlo, Netherlands) and cDNA generated 
with iScript (Bio-Rad, Hercules, CA, USA). Quantitative 
PCR was completed using SsoFast EVA Green Supermix 
(Bio-Rad). For HBZ expression, RNA was treated with 
DNase (Invitrogen) prior to RT-PCR. All steps were 
completed following the manufacturers instructions. 
Granzyme B (Forward-CCACTCTCGACCCTACATGG; 
Reverse-GGCCCCCAAAGTGACATTTATT), 
Cyclophilin A (Forward-AGCATACAGGTCCTGGCATC; 






Tissues were fixed in 10% formalin for paraffin 
embedding. Tibias were decalcified in 14% EDTA prior 
to paraffin embedding. 5µm sections were stained by 
immunohistochemistry (IHC) with rat anti-mouse CD45 
(BD Pharmingen #550539), CD3 (Dako #A0452), B220 
(BD Pharmingen #550286). Flag-tagged HBZ expression 
was detected following citrate antigen retrieval with the 
anti-flag antibody (Sigma #F1804, 5ug/ml) and detected 
using the HistoMouse-Plus Broad Spectrum (AEC) kit 
(Life Technologies, catalog #849541). Tibias were stained 
with the tartrate-resistant acid phosphatase (TRAP) 
(Sigma-Aldrich) to visualize osteoclasts. The number 
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and surface area of TRAP+ cells/ bone surface area were 
quantified at 5X magnification for WT (n = 7) and HBZ (n 
= 7) mice. Images were acquired using the NanoZoomer 
2.0-HT System (Hamamatsu Photonics) or the Zeiss Axio 
Scan Z1.
RNA in situ hybridization
Paraffin embedded tissue was stained for RNA via 
in situ hybridization (RNAscope Manual Assay 2.5HD 
- BROWN kit, ADC Biotechnology). Tissues were 
deparaffinized and pretreated with hydrogen peroxide, 
protease, and an antigen retrieval solution as directed. 
Antigen retrieval was performed in a pressure cooker for 
30 minutes followed by incubation with the HBZ probe 
or the provided negative and positive controls. The HBZ 
probe (ADC Biotechnology) has a target region from 
173-1363 in the HBZ RNA. The negative control probe 
hybridized the E. Coli gene DapB and the positive control 
probe hybridized the mouse housekeeping gene Ppib, 
Tissue sections were stained with DAB and hematoxylin, 
and mounted (Clearmount medium). Images were scanned 
using the Nanozoomer digital slide scanner (Hamamatsu 
Photonics). Five images at 60X magnification were taken 
randomly for each sample and positive cells/total cell 
number was quantified manually.
Tumor implantation
Cells were isolated from a spontaneous mesenteric 
Gzmb-HBZ tumor by mechanical disruption through a 
70um cell strainer and frozen in 7% DMSO containing 
media and stored in liquid nitrogen. NSG or Gzmb-HBZ 
mice were implanted by intravenous or intraperitoneal 
injection of 1x107 tumor cells following twice PBS 
washes. In the Gzmb-HBZ mice, the secondary tumor was 
isolated mechanically as described and frozen and stored 
in liquid nitrogen. Thawed cells were washed twice in PBS 
and i.v. implanted in NSG mice at 1x107 cells per mouse.
Flow cytometry
Spleens were mechanically disrupted through a 
70µm cell strainer. Cells were washed with PBS and red 
blood cells lysed (Sigma-Aldrich, #R7757). Cells were 
washed twice, centrifuged and blocked for 10 minutes on 
ice. Cells were resuspended in antibody diluent containing 
fluorophore-conjugated antibodies at 1:200 (ebioscience 
antibodies CD45, CD3e, CD4 and CD8). Cells were 
incubated 1 hour on ice, then washed twice in PBS and 
resuspended in FACS buffer (5% FBS in PBS) for analysis 
on the BD Bioscience LSRFortessa.
MicroCT of WT and Gzmb-HBZ tibiae
Tibiae were scanned by micro-computed 
tomography (μCT) (μCT-40; Scanco Medical). The 
trabecular region from forty 2D slices (0.8 mm) was 
selected using contours inside the cortical shell on each 
2D image, with the growth plate as a marker to determine 
a consistent location to start analysis. A 3D cubical voxel 
model of bone was built, and calculations were made 
for bone volume/tissue volume (BV/TV) and trabecular 
thickness (Tb.Th) and bone mineral density (BMD) 
calibrated against a hydroxyapatite phantom. A threshold 
of 300 (out of 1,000) was used to differentiate trabecular 
bone from non-bone.
Mouse cytokine serum array
Serum was collected from WT (n = 3) and Gzmb-
HBZ (n = 3) mice after 16 hours without food and 
was frozen at -80 degrees Celsius. Thawed serum was 
applied to a glass slide antibody array and processed 
according to manufacturer’s instructions (QAM-CYT-1-1, 
Raybiotech). Raybiotech completed slide scanning and 
data extraction. The primary author analyzed raw data. 
For analysis, background was subtracted and mean 
values were determined (3-4 replicates per cytokine) and 
converted from fluorescence unit to protein concentration 
by a standard curve best-fit regression specific for each 
cytokine. 
Ex vivo T cell culture
Spleens were gently mechanically disassociated 
through a 70um cell strainer. Isolated cells were plated 
in a tissue culture treated plate overnight at 37 degrees 
Celsius in media (RPMI, 5% FBS). Non-adherent cells 
were transferred to CD3e/CD28 coated 6-well plates in 
T cell media (RPMI, 5% FBS, 1% P/S, IL-2) for 24hrs at 
37 degrees Celsius. Cells were collected, rinsed in PBS 
and RNA isolated by RNeasy RNA isolation kit (Qiagen). 
Remaining cells were plated in 6-well tissue culture plates 
with T cell media, expanded for 3 days and analyzed by 
flow cytometry as described above.
Statistics
Data are shown as mean with error bars representing 
standard error of the mean (mean ± SEM), unless 
otherwise specified. Differences among experimental 
groups were analyzed using a two-tailed t-test or 
Fisher’s exact test (tumor incidence and WBC counts) as 
appropriate. Assumptions for t-test analyses (independent 
samples, approximately normal distributions) for samples 
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n > 5 were sufficiently met, or satisfied if a random sample 
of n ≤ 5 were selected from an approximately normally 
distributed population. For data where the sample number 
was too small to determine normality (n ≤ 5 independent 
samples or biological replicates), but where the variance 
between groups was similar (using the F-test for equality 
of variances), two-tailed t-test analyses [40] were used 
where appropriate. For non-normally distributed data, 
differences among experimental groups were analyzed 
using a two-tailed Mann-Whitney U-test for unpaired 
samples. All tests were considered significant at P ≤ 0.05. 
Data analyses were complete using Prism 6 (GraphPad 
Software).
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